Búsqueda | Biblioteca Virtual en Salud

1.

Responsibilities and risks when radiologists evaluate patients for child abuse.

Brown, Jeffrey L.

AJR Am J Roentgenol ; 200(5): 948-9, 2013 May.

Artículo en Inglés | MEDLINE | ID: mdl-23617473

2.

Trials and Tribulations.

Brown, Jeffrey L.

JAMA ; 318(7): 612-613, 2017 Aug 15.

Artículo en Inglés | MEDLINE | ID: mdl-28810028

3.

A piece of my mind: The unasked question.

Brown, Jeffrey L.

JAMA ; 308(18): 1869-70, 2012 Nov 14.

Artículo en Inglés | MEDLINE | ID: mdl-23150007

4.

Communication pitfalls of traditional history and physical write-up documentation.

Brown, Jeffrey L.

Adv Med Educ Pract ; 8: 37-41, 2017.

Artículo en Inglés | MEDLINE | ID: mdl-28096709

5.

Selective Androgen Receptor Modulator RAD140 Inhibits the Growth of Androgen/Estrogen Receptor-Positive Breast Cancer Models with a Distinct Mechanism of Action.

Yu, Ziyang; He, Suqin; Wang, Dannie; Patel, Hitisha K; Miller, Chris P; Brown, Jeffrey L; Hattersley, Gary; Saeh, Jamal C.

Clin Cancer Res ; 23(24): 7608-7620, 2017 Dec 15.

Artículo en Inglés | MEDLINE | ID: mdl-28974548

6.

Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER⁺ Breast Cancer Patient-derived Xenograft Models.

Bihani, Teeru; Patel, Hitisha K; Arlt, Heike; Tao, Nianjun; Jiang, Hai; Brown, Jeffrey L; Purandare, Dinesh M; Hattersley, Gary; Garner, Fiona.

Clin Cancer Res ; 23(16): 4793-4804, 2017 Aug 15.

Artículo en Inglés | MEDLINE | ID: mdl-28473534

7.

Brendan C. Stack, The Father of TMJ Treatment.

Brown, Jeffrey L.

Cranio ; 38(6): 357, 2020 Nov.

Artículo en Inglés | MEDLINE | ID: mdl-33044903

8.

A novel uHPLC-MS/MS method for the quantitation of AZD7451 (AZ12607092) in human plasma.

Peer, Cody J; Brown, Jeffrey L; Martin, Timothy J; Roth, Jeffrey; Spencer, Shawn D; Brassil, Patrick; McNeill, Katharine A; Kreisl, Teri N; Fine, Howard A; Figg, William D.

J Chromatogr B Analyt Technol Biomed Life Sci ; 942-943: 107-12, 2013 Dec 30.

Artículo en Inglés | MEDLINE | ID: mdl-24239935

9.

Physician Exposure to Direct-to-Consumer Pharmaceutical Marketing: Potential for Creating Prescribing Bias.

Brown, Jeffrey L.

Am J Med ; 130(6): e247-e248, 2017 Jun.

Artículo en Inglés | MEDLINE | ID: mdl-28089801

10.

Inhibition of the hedgehog pathway targets the tumor-associated stroma in pancreatic cancer.

Hwang, Rosa F; Moore, Todd T; Hattersley, Maureen Mertens; Scarpitti, Meghan; Yang, Bin; Devereaux, Erik; Ramachandran, Vijaya; Arumugam, Thiruvengadam; Ji, Baoan; Logsdon, Craig D; Brown, Jeffrey L; Godin, Robert.

Mol Cancer Res ; 10(9): 1147-57, 2012 Sep.

Artículo en Inglés | MEDLINE | ID: mdl-22859707

11.

AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts.

Iyer, Radhika; Varela, Carly R; Minturn, Jane E; Ho, Ruth; Simpson, Anisha M; Light, Jennifer E; Evans, Audrey E; Zhao, Huaqing; Thress, Kenneth; Brown, Jeffrey L; Brodeur, Garrett M.

Cancer Chemother Pharmacol ; 70(3): 477-86, 2012 Sep.

Artículo en Inglés | MEDLINE | ID: mdl-22623209

12.

The Importance of Taking a Military History.

Burgo-Black, A Lucile; Brown, Jeffrey L; Boyce, Ross M; Hunt, Stephen C.

Public Health Rep ; 131(5): 711-713, 2016 09.

Artículo en Inglés | MEDLINE | ID: mdl-28123212

13.

The selective Trk inhibitor AZ623 inhibits brain-derived neurotrophic factor-mediated neuroblastoma cell proliferation and signaling and is synergistic with topotecan.

Zage, Peter E; Graham, Timothy C; Zeng, Lizhi; Fang, Wendy; Pien, Christine; Thress, Ken; Omer, Charles; Brown, Jeffrey L; Zweidler-McKay, Patrick A.

Cancer ; 117(6): 1321-91, 2011 Mar 15.

Artículo en Inglés | MEDLINE | ID: mdl-20960503

14.

Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells.

Mazzieri, Roberta; Pucci, Ferdinando; Moi, Davide; Zonari, Erika; Ranghetti, Anna; Berti, Alvise; Politi, Letterio S; Gentner, Bernhard; Brown, Jeffrey L; Naldini, Luigi; De Palma, Michele.

Cancer Cell ; 19(4): 512-26, 2011 Apr 12.

Artículo en Inglés | MEDLINE | ID: mdl-21481792

15.

Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition.

Parsels, Leslie A; Qian, Yushen; Tanska, Daria M; Gross, Marisa; Zhao, Lili; Hassan, Maria C; Arumugarajah, Sankari; Parsels, Joshua D; Hylander-Gans, Linda; Simeone, Diane M; Morosini, Deborah; Brown, Jeffrey L; Zabludoff, Sonya D; Maybaum, Jonathan; Lawrence, Theodore S; Morgan, Meredith A.

Clin Cancer Res ; 17(11): 3706-15, 2011 Jun 01.

Artículo en Inglés | MEDLINE | ID: mdl-21482692

16.

Theraputic targeting of Trk supresses tumor proliferation and enhances cisplatin activity in HNSCC.

Yilmaz, Turker; Jiffar, Tilahun; de la Garza, Gabriel; Lin, Heather; Milas, Zvonimir; Takahashi, Yoko; Hanna, Ehab; MacIntyre, Terry; Brown, Jeffrey L; Myers, Jeffrey N; Kupferman, Michael E.

Cancer Biol Ther ; 10(6): 644-53, 2010 Sep 15.

Artículo en Inglés | MEDLINE | ID: mdl-20703101

17.

A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models.

Brown, Jeffrey L; Cao, Z Alexander; Pinzon-Ortiz, Maria; Kendrew, Jane; Reimer, Corinne; Wen, Shenghua; Zhou, Joe Q; Tabrizi, Mohammad; Emery, Steve; McDermott, Brenda; Pablo, Lourdes; McCoon, Patricia; Bedian, Vahe; Blakey, David C.

Mol Cancer Ther ; 9(1): 145-56, 2010 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-20053776

18.

Exertional dysnatremia in collapsed marathon runners: a critical role for point-of-care testing to guide appropriate therapy.

Siegel, Arthur J; d'Hemecourt, Pierre; Adner, Marvin M; Shirey, Terry; Brown, Jeffrey L; Lewandrowski, Kent B.

Am J Clin Pathol ; 132(3): 336-40, 2009 Sep.

Artículo en Inglés | MEDLINE | ID: mdl-19687309

19.

Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway.

Thress, Kenneth; Macintyre, Terry; Wang, Haiyun; Whitston, Dave; Liu, Zhong-Ying; Hoffmann, Ethan; Wang, Tao; Brown, Jeffrey L; Webster, Kevin; Omer, Charles; Zage, Peter E; Zeng, Lizhi; Zweidler-McKay, Patrick A.

Mol Cancer Ther ; 8(7): 1818-27, 2009 Jul.

Artículo en Inglés | MEDLINE | ID: mdl-19509272

20.

Ethical clinical practice and sport psychology: when two worlds collide.

Brown, Jeffrey L; Cogan, Karen D.

Ethics Behav ; 16(1): 15-23, 2006.

Artículo en Inglés | MEDLINE | ID: mdl-17036422

Biblioteca Virtual en Salud

Hipertensión

Su selección (0)

Formato de exportación:

Exportar:

Responsibilities and risks when radiologists evaluate patients for child abuse.

Trials and Tribulations.

A piece of my mind: The unasked question.

Communication pitfalls of traditional history and physical write-up documentation.

Selective Androgen Receptor Modulator RAD140 Inhibits the Growth of Androgen/Estrogen Receptor-Positive Breast Cancer Models with a Distinct Mechanism of Action.

Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER⁺ Breast Cancer Patient-derived Xenograft Models.

Brendan C. Stack, The Father of TMJ Treatment.

A novel uHPLC-MS/MS method for the quantitation of AZD7451 (AZ12607092) in human plasma.

Physician Exposure to Direct-to-Consumer Pharmaceutical Marketing: Potential for Creating Prescribing Bias.

Inhibition of the hedgehog pathway targets the tumor-associated stroma in pancreatic cancer.

AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts.

The Importance of Taking a Military History.

The selective Trk inhibitor AZ623 inhibits brain-derived neurotrophic factor-mediated neuroblastoma cell proliferation and signaling and is synergistic with topotecan.

Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells.

Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition.

Theraputic targeting of Trk supresses tumor proliferation and enhances cisplatin activity in HNSCC.

A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models.

Exertional dysnatremia in collapsed marathon runners: a critical role for point-of-care testing to guide appropriate therapy.

Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway.

Ethical clinical practice and sport psychology: when two worlds collide.